<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-0108</journal-id>
<journal-title><![CDATA[Revista Española de Enfermedades Digestivas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. esp. enferm. dig.]]></abbrev-journal-title>
<issn>1130-0108</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Española de Patología Digestiva]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-01082018001100011</article-id>
<article-id pub-id-type="doi">10.17235/reed.2018.5429/2017</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Mesalazina administrada de forma tópica como causa de síndrome de Stevens-Johnson]]></article-title>
<article-title xml:lang="en"><![CDATA[Topical mesalazine as a cause of Stevens-Johnson syndrome]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Núñez-Ortiz]]></surname>
<given-names><![CDATA[Andrea]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Trigo-Salado]]></surname>
<given-names><![CDATA[Claudio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[de-la-Cruz-Ramírez]]></surname>
<given-names><![CDATA[María-Dolores]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Herrera-Justiniano]]></surname>
<given-names><![CDATA[José-Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Leo-Carnerero]]></surname>
<given-names><![CDATA[Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario Virgen del Rocío U.G.C. Aparato Digestivo ]]></institution>
<addr-line><![CDATA[Sevilla ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>11</month>
<year>2018</year>
</pub-date>
<volume>110</volume>
<numero>11</numero>
<fpage>736</fpage>
<lpage>738</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-01082018001100011&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-01082018001100011&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-01082018001100011&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La mesalazina es un fármaco usado habitualmente en la colitis ulcerosa que suele cursar con pocos efectos secundarios. Se han descrito casos infrecuentes de lesiones mucocutáneas graves como el síndrome de Stevens-Johnson (SSJ) y la necrólisis epidérmica tóxica (NET) secundarias a salicilatos. Es importante su diagnóstico precoz por su alta morbimortalidad. Presentamos el caso de una mujer de 46 años con proctitis ulcerosa que desarrolló un SSJ tras la administración tópica de mesalazina. La evolución de las lesiones fue favorable tras la suspensión del fármaco e inicio de corticoides intravenosos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Mesalazine is a drug routinely used in ulcerative colitis and usually has few side effects. There have been reports of uncommon cases of severe mucocutaneous damage, such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), induced by salicylates. It is important to diagnose these promptly due to the high morbidity and mortality rates. We describe the case of a 46-year-old female with ulcerative proctitis, who developed SJS following topical mesalazine use. The lesions responded well to intravenous corticosteroids after discontinuation of the drug.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Mesalazina]]></kwd>
<kwd lng="es"><![CDATA[Síndrome de Stevens-Johnson]]></kwd>
<kwd lng="es"><![CDATA[Necrólisis epidérmica tóxica]]></kwd>
<kwd lng="en"><![CDATA[Mesalazine]]></kwd>
<kwd lng="en"><![CDATA[Stevens-Johnson syndrome]]></kwd>
<kwd lng="en"><![CDATA[Toxic epidermal necrolysis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Erythroderma and toxic epidermal necrolysis caused by to 5-aminosalacylic acid]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lemoli]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Piconi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ardizzone]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Inflamm Bowel Dis]]></source>
<year>2006</year>
<volume>12</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1007-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Toxic epidermal necrosis associated with mesalamine in a patient with ulcerative colitis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fukunaga]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ohda]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Inoue]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Inflamm Bowel Dis]]></source>
<year>2007</year>
<volume>13</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1055-6</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[U K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Creamer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Walsh]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Dziewulski]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Br J Dermatol]]></source>
<year>2016</year>
<volume>174</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1194-227</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Toxic epidermal necrolysis part I. Introduction, history, clinical features, systemic manifestations, etiology and inmunopathogenesis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[McDonough]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2013</year>
<volume>69</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>173e1-13</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Toxic epidermal necrolysis part I. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[McDonough]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2013</year>
<volume>69</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>187e1-16</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Stevens-Johnson syndrome and toxic epidermal necrolysis standard reporting and evaluation guidelines results of a National Institutes of Health Working Group]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maverakis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Shinkai]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[JAMA Dermatol]]></source>
<year>2017</year>
<volume>153</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>587-92</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Síndrome de Stevens-Johnson y necrólisis epidérmica tóxica revisión de la experiencia clínica en un Hospital Universitario (1989-2008)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferrándiz-Pulido]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[García-Fernández]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Morel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Med Clin]]></source>
<year>2011</year>
<volume>136</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>583-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis comparison with case-control analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sassolas]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Haddad]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mockenhaupt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>2010</year>
<volume>88</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>60-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tremblay]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stevens-Johnson syndrome with sulfasalazine treatment report of two cases]]></article-title>
<collab>Pineton de Chambrun G.De Vroey B</collab>
<source><![CDATA[J Crohns Colitis]]></source>
<year>2011</year>
<volume>5</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>457-60</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
